Studies have shown that 44.4% of LCC patients expressed PDL1 in tumor cells,11 and PDL1 TPS ≥ 50% was found in 40% of LCC.12 According to NCCN guidelines, immunotherapy or immunotherapy combined with chemotherapy is recommended for first‐line therapy in patients with negative driver genes, with no contraindications for immunotherapy, and PD‐L1 expression ≥1%.32 This evidence concerns the gene CD274 and leukoencephalopathy with calcifications and cysts.